» Authors » Kevin V Lemley

Kevin V Lemley

Explore the profile of Kevin V Lemley including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 86
Citations 2393
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Mariani L, Eddy S, Alakwaa F, McCown P, Harder J, Nair V, et al.
Kidney Int . 2022 Nov; 103(3):565-579. PMID: 36442540
The diagnosis of nephrotic syndrome relies on clinical presentation and descriptive patterns of injury on kidney biopsies, but not specific to underlying pathobiology. Consequently, there are variable rates of progression...
12.
Gipson D, Troost J, Spino C, Attalla S, Tarnoff J, Massengill S, et al.
JAMA Netw Open . 2022 Aug; 5(8):e2228701. PMID: 36006643
Importance: Focal segmental glomerulosclerosis (FSGS) is a common cause of end-stage kidney disease (ESKD) across the lifespan. While 10% to 15% of children and 3% of adults who develop ESKD...
13.
Lemley K
Kidney360 . 2022 Apr; 3(1):1-2. PMID: 35368576
No abstract available.
14.
Wang C, Troost J, Wang Y, Greenbaum L, Gibson K, Trachtman H, et al.
Pediatr Nephrol . 2021 Nov; 37(7):1585-1595. PMID: 34796395
Background: Pediatric patients with nephrotic syndrome take medications long-term with significant toxicity and complex regimens, yet data on medication adherence are limited. Methods: In a multicenter observational study of patients...
15.
Gyarmati G, Shroff U, Izuhara A, Hou X, Da Sacco S, Sedrakyan S, et al.
JCI Insight . 2021 Nov; 7(1). PMID: 34793332
Alport syndrome (AS) is a genetic disorder caused by mutations in type IV collagen that lead to defective glomerular basement membrane, glomerular filtration barrier (GFB) damage, and progressive chronic kidney...
16.
Frank C, Hou X, Petrosyan A, Villani V, Zhao R, Hansen J, et al.
Kidney Int . 2021 Sep; 101(1):106-118. PMID: 34562503
Progression of glomerulosclerosis is associated with loss of podocytes with subsequent glomerular tuft instability. It is thought that a diminished number of podocytes may be able to preserve tuft stability...
17.
Banu K, Lin Q, Basgen J, Planoutene M, Wei C, Reghuvaran A, et al.
JCI Insight . 2021 Sep; 6(19). PMID: 34473647
Herein, we report that Shroom3 knockdown, via Fyn inhibition, induced albuminuria with foot process effacement (FPE) without focal segmental glomerulosclerosis (FSGS) or podocytopenia. Interestingly, knockdown mice had reduced podocyte volumes....
18.
Nelson R, Knowler W, Kretzler M, Lemley K, Looker H, Mauer M, et al.
Diabetes . 2021 Jul; 70(8):1603-1616. PMID: 34285119
Prospective studies in informative populations are crucial to increasing our knowledge of disease. In this perspective, we describe a half century of studies in an American Indian population that transformed...
19.
Zee J, McNulty M, Hodgin J, Zhdanova O, Hingorani S, Jefferson J, et al.
Pediatr Nephrol . 2021 Mar; 36(9):2747-2757. PMID: 33646395
Background: The G1 and G2 alleles of apolipoprotein L1 (APOL1) are common in the Black population and associated with increased risk of focal segmental glomerulosclerosis (FSGS). The molecular mechanisms linking...
20.
Troost J, Waldo A, Carlozzi N, Murphy S, Modersitzki F, Trachtman H, et al.
Clin Kidney J . 2020 Sep; 13(4):597-606. PMID: 32905199
Background: Understanding the relationship between clinical and patient-reported outcomes (PROs) will help support clinical care and future clinical trial design of novel therapies for focal segmental glomerulosclerosis (FSGS). Methods: FSGS...